Production of recombinant coagulation factors: Are humans the best host cells?

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Bioengineered

• Publication date

  2017-02-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/21655979.2017.1279767PMID 28277160PMCID PMC5639856
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunogenicity of long-lasting recombinant factor VIII products.

  2016cited by this paper
• The past and future of haemophilia: diagnosis, treatments, and its complications.

  2016cited by this paper
• Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).

  2016cited by this paper
• Characterization of IXINITY® (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph

  2016cited by this paper
• Human cell lines: A promising alternative for recombinant FIX production.

  2016cited by this paper
• Prophylaxis vs. on‐demand treatment with Nuwiq® (Human‐cl rhFVIII) in adults with severe haemophilia A

  2016cited by this paper
• Novel, human cell line‐derived recombinant factor VIII (human‐cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety

  2016cited by this paper
• A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.

  2016cited by this paper
• Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.

  2016cited by this paper
• Novel, human cell line‐derived recombinant factor VIII (Human‐cl rhFVIII, Nuwiq®) in children with severe haemophilia A: efficacy, safety and pharmacokinetics

  2016cited by this paper
• New developments in the management of moderate-to-severe hemophilia B

  2016cited by this paper
• Serum-free suspension culturing of human cells: adaptation, growth, and cryopreservation

  2015cited by this paper
• The art of CHO cell engineering: A comprehensive retrospect and future perspectives.

  2015cited by this paper
• Industrial production of clotting factors: Challenges of expression, and choice of host cells

  2015cited by this paper
• Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein.

  2015cited by this paper
• Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.

  2015cited by this paper
• Safety of PEGylated recombinant human full‐length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates

  2015cited by this paper
• Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives

  2015cited by this paper
• Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011.

  2014cited by this paper
• Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A.

  2014cited by this paper
• The choice of mammalian cell host and possibilities for glycosylation engineering.

  2014cited by this paper
• A new recombinant factor VIII: from genetics to clinical use

  2014cited by this paper
• Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein

  2014cited by this paper
• Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII.

  2013cited by this paper
• Production of recombinant therapeutic proteins in human cells: current achievements and future perspectives.

  2013cited by this paper
• Factor VIII products and inhibitor development in severe hemophilia A.

  2013cited by this paper
• Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity

  2013cited by this paper
• Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

  2013cited by this paper
• SK-HEP cells and lentiviral vector for production of human recombinant factor VIII

  2012cited by this paper
• Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

  2012cited by this paper
• Longer FVIII: the 4th generation.

  2012cited by this paper
• Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation

  2012cited by this paper
• A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

  2012cited by this paper
• The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics

  2012cited by this paper
• Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII.

  2012cited by this paper
• CHO cells in biotechnology for production of recombinant proteins: current state and further potential

  2011cited by this paper
• BAX 855, a PEGylated rFVIII product with prolonged half-life

  2011cited by this paper
• Potential impact of the non‐human sialic acid N‐glycolylneuraminic acid on transplant rejection risk

  2011cited by this paper
• Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.

  2010cited by this paper
• Expression systems for therapeutic glycoprotein production.

  2009cited by this paper
• Recombinant clotting factors

  2008cited by this paper
• Recombinant expression of coagulation factor VIII in hepatic and non-hepatic cell lines stably transduced with third generation lentiviral vectors comprising the minimal factor VIII promoter.

  2007cited by this paper
• Reformulated BeneFix®: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B

  2007cited by this paper
• Expression of human coagulation factor VIII in a human hybrid cell line, HKB11

  2006cited by this paper
• Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells

  2004cited by this paper
• Inhibitors in haemophilia: pathophysiology

  2004cited by this paper
• Affinity chromatography techniques based on the immobilisation of peptides exhibiting specific binding activity.

  2003cited by this paper
• An adventure in biotechnology: the development of haemophilia A therapeutics – from whole‐blood transfusion to recombinant DNA to gene therapy

  2002cited by this paper
• New‐generation recombinant factor concentrates: bridge to gene therapy

  2001cited by this paper
• Human Hybrid Host Cell for Mammalian Gene Expression

  1999cited by this paper
• Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction.

  1993cited by this paper
• Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma.

  1992cited by this paper
• Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization.

  1989cited by this paper
• Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments.

  1985cited by this paper
• Inactivation of viruses in labile blood derivatives. I. Disruption of lipid‐enveloped viruses by tri(n‐butyl)phosphate detergent combinations

  1985cited by this paper
• Production of high-potency concentrates of antihemophilic globulin in a closed-bag system.

  1965influential reference
• An Enzyme Cascade in the Blood Clotting Mechanism, and its Function as a Biochemical Amplifier

  1964cited by this paper
• AN ENZYME CASCADE IN THE BLOOD CLOTTING MECHANISM, AND ITS FUNCTION AS A BIOCHEMICAL AMPLIFIER

  1964cited by this paper

• A Comparative Review on the Production of Factor VIII in Human and Non-human Hosts.

  2025cites this paper
• Recombinant Proteins: Evolution to their Therapeutic Potential.

  2025cites this paper
• Optimized Production and Coagulation Activity of rhFVII in HEK293 Cells for Bleeding Disorders.

  2025cites this paper
• Emicizumab as a Promising Form of Therapy for Type A Hemophilia - A Review of Current Knowledge from Clinical Trials.

  2024cites this paper
• Formulations with Active Plant Molecules and Additional Therapies in Wound Healing

  2024cites this paper
• A review of fetal cell lines used during drug development: Focus on COVID-19 vaccines, transplant medications, and biologics.

  2024cites this paper
• Advances and challenges in the purification of recombinant coagulation factors: A review.

  2024cites this paper
• Strategies for Hemophilia Treatment, a literature review of current evidence

  2023cites this paper
• Animal Transgenesis and Cloning: Combined Development and Future Perspectives.

  2023cites this paper
• Management of Urgent Bleeding in Patients with Hemophilia A: Focus on the Use of Emicizumab

  2023cites this paper
• Recent advances in the production of recombinant factor IX: bioprocessing and cell engineering

  2022cites this paper
• Evaluation of different expression systems for the heterologous production of sprivivirus glycoprotein

  2022cites this paper
• Engineering CRISPR/Cas9 for Multiplexed Recombinant Coagulation Factor Production

  2022cites this paper
• Hepatitis C Virus Infections in Patients with Hemophilia: Links, Risks and Management

  2022cites this paper
• Modified expi293 cell culture system using piggyBac transposon enables efficient production of human FVIII

  2022cites this paper
• AryoSeven RT (Coagulation factor VIIa, recombinant) safety and efficacy study among congenial factor VII deficient patients in Iraq

  2022cites this paper
• Biological activity of a new recombinant human coagulation factor VIII and its efficacy in a small animal model.

  2022cites this paper
• Total Knee arthroplasty in Haemophilia: survivorship and outcomes - a systematic review and meta-analysis.

  2021cites this paper
• Bioprocess Intensification: Technologies and Goals

  2021cites this paper
• Recent Advances in Supramolecular Affinity Separations: Affinity Chromatography and Related Methods.

  2021cites this paper
• In silico computation of coagulation factor II: a potential water treatment agent against gram negative bacteria

  2021cites this paper
• Polysaccharide-based chromatographic adsorbents for virus purification and viral clearance

  2020cites this paper
• Status of Biologic Drugs in Modern Therapeutics‐Targeted Therapies vs. Small Molecule Drugs

  2020cites this paper
• Protein Therapeutics from Monolayer to Spheroids- A Model for Preclinical Investigations

  2020cites this paper
• Therapeutic proteases from plants: biopharmaceuticals with multiple applications

  2019cites this paper
• Genetic engineering approaches to improve posttranslational modification of biopharmaceuticals in different production platforms

  2019cites this paper
• Critical Evaluation of Strategies for the Production of Blood Coagulation Factors in Plant-Based Systems

  2019cites this paper
• Extended D-E knob-hole interaction sites in fibrin polymerisation, clot formation and clot mechanics

  2019cites this paper
• The role of magnetic field in the biopharmaceutical production: Current perspectives

  2019cites this paper
• Design of Optimal CHO Protein N-glycosylation Profiles

  2018cites this paper
• Platforms for Recombinant Therapeutic Glycoprotein Production.

  2018cites this paper
• Navigating Speed Bumps on the Innovation Highway in Hemophilia Therapeutics

  2018cites this paper
• Gene Therapy Approaches To Immune Tolerance Induction In Canine Hemophilia

  2018cites this paper
• Human Embryonic Kidney 293 Cells: A Vehicle for Biopharmaceutical Manufacturing, Structural Biology, and Electrophysiology

  2018cites this paper